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BACKGROUND
Diabetic ketoacidosis in children may cause brain injuries ranging from mild to severe. 
Whether intravenous fluids contribute to these injuries has been debated for decades.
METHODS
We conducted a 13-center, randomized, controlled trial that examined the effects of the 
rate of administration and the sodium chloride content of intravenous fluids on neuro-
logic outcomes in children with diabetic ketoacidosis. Children were randomly assigned to 
one of four treatment groups in a 2-by-2 factorial design (0.9% or 0.45% sodium chloride 
content and rapid or slow rate of administration). The primary outcome was a decline in 
mental status (two consecutive Glasgow Coma Scale scores of <14, on a scale ranging from 
3 to 15, with lower scores indicating worse mental status) during treatment for diabetic 
ketoacidosis. Secondary outcomes included clinically apparent brain injury during treat-
ment for diabetic ketoacidosis, short-term memory during treatment for diabetic keto-
acidosis, and memory and IQ 2 to 6 months after recovery from diabetic ketoacidosis.
RESULTS
A total of 1389 episodes of diabetic ketoacidosis were reported in 1255 children. The 
Glasgow Coma Scale score declined to less than 14 in 48 episodes (3.5%), and clinically 
apparent brain injury occurred in 12 episodes (0.9%). No significant differences among the 
treatment groups were observed with respect to the percentage of episodes in which the 
Glasgow Coma Scale score declined to below 14, the magnitude of decline in the Glasgow 
Coma Scale score, or the duration of time in which the Glasgow Coma Scale score was less 
than 14; with respect to the results of the tests of short-term memory; or with respect to 
the incidence of clinically apparent brain injury during treatment for diabetic ketoacidosis. 
Memory and IQ scores obtained after the children’s recovery from diabetic ketoacidosis also 
did not differ significantly among the groups. Serious adverse events other than altered 
mental status were rare and occurred with similar frequency in all treatment groups.
CONCLUSIONS
Neither the rate of administration nor the sodium chloride content of intravenous fluids 
significantly influenced neurologic outcomes in children with diabetic ketoacidosis. 
(Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human 
Development and the Health Resources and Services Administration; PECARN DKA 
FLUID ClinicalTrials.gov number, NCT00629707.)
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Clinically apparent brain injuries occur in 0.5 to 0.9% of episodes of dia-betic ketoacidosis in children; these brain 
injuries manifest as sudden neurologic decline 
and are often associated with morbidity and 
mortality.1-3 Among patients without obvious neu-
rologic decline during treatment for diabetic 
ketoacidosis, subtle neurologic alterations are 
often present after recovery, including deficits in 
memory, attention, and IQ4-7 and changes in cere-
bral microstructure.4,8,9
Early theories to explain diabetic ketoacidosis–
related brain injury suggested that rapid admin-
istration of intravenous fluids reduces serum 
osmolality, which results in brain swelling.10,11 
Therefore, many treatment protocols for diabetic 
ketoacidosis in children advocate slow rehydra-
tion with isotonic fluids. Retrospective reviews 
have been used to support these strategies; how-
ever, those studies are subject to bias owing to 
the higher rates of brain injury that have been 
seen in children who are more dehydrated2 and 
therefore receive larger volumes of f luid. In ad-
dition, such studies have often included patients 
who had been selectively referred because of the 
severity of their illness from facilities that were 
often not specifically pediatric centers and that 
used treatment protocols that differed from those 
at pediatric centers.10,12,13 Rates of clinically ap-
parent brain injury have remained stable over 
time,2,14,15 and properly controlled retrospective 
studies have not shown associations between the 
fluid administration rate and brain injury.2,3 In-
stead, data suggest that brain injury may result 
from abnormalities in cerebral perfusion and 
inflammation that occur during episodes of dia-
betic ketoacidosis.2,16 In the current trial, we in-
vestigated the effects of specific intravenous fluid 
regimens on neurologic outcomes in children 
with diabetic ketoacidosis.
Me thods
Overview of the Trial
We conducted this randomized, controlled trial 
at 13 emergency departments in the Pediatric 
Emergency Care Applied Research Network 
(PECARN), all of which were located in urban 
centers in the United States. We used a 2-by-2 
factorial design to compare four rehydration 
treatment regimens in children with diabetic 
ketoacidosis (Table 1).17 We evaluated the effects 
of rehydration rate and fluid sodium chloride 
content on neurocognitive outcomes, including 
neurologic status during the episode of diabetic 
ketoacidosis and memory and IQ after recovery 
from diabetic ketoacidosis. Details of the trial 
methods were published previously17 and are 
also provided in the protocol, available with the 
full text of this article at NEJM.org.
Trial Oversight
The trial was designed by the first and last au-
thors (principal investigators), with input from 
site investigators; collaborators from the PECARN 
data coordinating center; the PECARN quality, 
safety, and regulatory affairs subcommittee; the 
PECARN protocol review and development sub-
committee; and the PECARN grant writing and 
publications subcommittee. Research coordina-
tors collected the data under the supervision of 
the site investigators. The PECARN data coordi-
nating center was responsible for data quality 
control and analyses. A data and safety monitor-
ing board, which oversaw the conduct of the 
trial, included an expert in each of the following 
disciplines: emergency medicine, pediatric criti-
cal care, pediatric endocrinology, neuropsychol-
ogy, and biostatistics. The data and safety moni-
toring board convened before enrollment, at the 
time of three scheduled interim efficacy analy-
ses, and at the time of four additional scheduled 
reviews of safety, enrollment, and follow-up data. 
The authors vouch for the accuracy and com-
pleteness of the data and analyses and for the 
fidelity of the trial to the protocol. There was no 
industry funding for this trial, and there were 
no agreements concerning confidentiality of the 
data between the sponsor and the authors or insti-
tutions. All the authors reviewed drafts of the 
manuscript and agreed with the decision to sub-
mit the manuscript for publication.
Patients
Children were eligible for enrollment in the trial 
if they were between 0 and 18 years of age and 
had received a diagnosis of diabetic ketoacidosis 
(defined as a blood glucose level of >300 mg 
per deciliter [16.7 mmol per liter] and either a 
venous pH of <7.25 or a serum bicarbonate level 
of <15 mmol per liter). Key exclusion criteria17 
were underlying disorders that could affect men-
tal status testing or neurocognitive evaluation; 
concurrent alcohol or narcotics use, head trauma, 
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NEJM.org
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or other conditions that could affect neurologic 
function; diabetic ketoacidosis for which the pa-
tient had already received substantial treatment; 
known pregnancy; or factors for which treating 
physicians determined that a specific fluid and 
electrolyte therapy was necessary. Children who 
presented with a Glasgow Coma Scale score of 
11 or lower (on a scale ranging from 3 to 15, 
with lower scores indicating worse mental sta-
tus) were excluded after year 2 because many 
participating clinicians believed that fluid regi-
mens for such children should not be deter-
mined on the basis of randomization.
Treatments
Written informed consent was obtained from 
the parents or guardians of all enrolled patients. 
Assent was obtained from patients whose age 
met the minimum age for assent according to 
their local institutional review board. Children 
were then randomly assigned to one of four 
treatment regimens: fast rate of rehydration with 
fluid that had 0.45% sodium chloride content, 
fast rate of rehydration with fluid that had 0.9% 
sodium chloride content, slow rate of rehydra-
tion with fluid that had 0.45% sodium chloride 
content, and slow rate of rehydration with fluid 
that had 0.9% sodium chloride content. Details of 
the treatment regimens are provided in Table 1. 
Randomization was stratified according to base-
line Glasgow Coma Scale score (14 or 15 vs. <14) 
and center (if the Glasgow Coma Scale score was 
<14).17 To avoid excessive restriction of the popu-
lation available for enrollment, patients who had 
previously undergone randomization and subse-
quently had another episode of diabetic keto-
acidosis during the trial were eligible to undergo 
randomization a second time. A patient could 
undergo randomization no more than twice. Ad-
ditional details are provided in the Statistical 
Analysis section and in the protocol.
Treatment for diabetic ketoacidosis other than 
the rate of administration and the sodium chlo-
ride content of the fluid was identical in the four 
treatment groups.17 After administration of in-
travenous fluid boluses, insulin treatment was 
initiated as a continuous intravenous infusion at 
a rate of 0.1 U per kilogram of body weight per 
hour. To prevent hypoglycemia during insulin 
treatment, dextrose was added to the study fluids 
when the serum glucose level declined below 
200 to 300 mg per deciliter (11.1 to 16.7 mmol T
ab
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per liter). Patients and their parents or guardians 
were unaware of the treatment-group assign-
ments. It was not possible for clinicians to be 
unaware of the treatment-group assignments 
because of the need to know the fluid protocol 
for clinical decision making.
Outcomes
The primary trial outcome was deterioration of 
neurologic status (as evidenced by two consecu-
tive Glasgow Coma Scale scores of <14 during 
any hour within the first 24 hours of treatment 
for diabetic ketoacidosis). Secondary outcomes 
included short-term memory during treatment 
for diabetic ketoacidosis (forward and backward 
digit-span recall; scores range from 0 to 16, with 
higher scores indicating better short-term mem-
ory)18; clinically apparent brain injury (defined as 
a deterioration in neurologic status leading to 
initiation of hyperosmolar therapy or endotra-
cheal intubation or resulting in death) during 
treatment for diabetic ketoacidosis; and short-
term memory, contextual memory, and IQ 2 to 
6 months after the episode of diabetic ketoacido-
sis. In the digit span test, participants are asked 
to repeat a sequence of numbers presented orally. 
In the “forward” task, participants are asked to 
repeat numbers in order, as presented. In the 
“backward” task, participants are asked to list 
the numbers in reverse order. The test stops 
when participants report the incorrect sequence 
twice for a given digit-span length.
To address variations in the diagnosis of 
clinically apparent brain injury, records of en-
counters with patients in which hyperosmolar 
therapy, endotracheal intubation, or death were 
documented were reviewed by an adjudication 
committee that included two pediatric critical 
care physicians and one pediatric emergency 
medicine physician, all of whom were unaware 
of the treatment-group assignments. Committee 
members confirmed or rejected each diagnosis 
of clinically apparent brain injury on the basis of 
published criteria.19
Assessments
Assessments of Mental Status
Glasgow Coma Scale scores were assessed at 
enrollment and hourly thereafter. Glasgow Coma 
Scale scores of less than 14 were confirmed by 
repeating the test 15 minutes later. For children 
3 years of age or older, digit-span tests were 
conducted at enrollment and every 4 hours 
thereafter during normal waking hours. Glasgow 
Coma Scale and digit-span assessments contin-
ued for 24 hours or until resolution of diabetic 
ketoacidosis (as defined by the transition to 
subcutaneous insulin) if diabetic ketoacidosis 
resolved before the 24-hour time point.
Assessments of Memory Function and IQ
Patients 3 to 18 years of age were asked to return 
2 to 4 months after discharge from the hospital 
for neurocognitive assessment but were allowed 
to return up to 6 months after discharge. Neuro-
cognitive testing was rescheduled in the event of 
either hypoglycemia (defined as a glucose level 
of <70 mg per deciliter [3.9 mmol per liter]) or 
ketosis (defined as the presence of moderate or 
large urine ketones).
IQ was evaluated with the use of the Wechsler 
Abbreviated Scale of Intelligence20 (in patients 
6 years of age or older) and the Wechsler Pre-
school and Primary Scale of Intelligence short 
form (in patients 3 to 5 years of age).21 At the 
same testing session, the digit-span test was re-
peated, and contextual memory was assessed 
with color and spatial-position tasks,17 which 
evaluated item recognition and recollection of 
contextual detail. Shorter and simpler versions 
of these tasks were used for children 3 to 5 years 
of age.17 Research personnel who conducted the 
cognitive testing and recorded outcome data were 
unaware of the treatment-group assignments, as 
were the trial investigators who oversaw this 
process.
Statistical Analysis
The primary analyses were performed according 
to the intention-to-treat principle. We also per-
formed secondary analyses in the per-protocol 
population (which included patients who under-
went randomization and received trial fluids per 
the protocol) and in the safety population (which 
included all patients who received any trial fluid) 
(details are provided in the protocol). Patients 
who had Glasgow Coma Scale scores of 14 or 15 
at baseline were included in the primary analy-
ses. Because patients who had Glasgow Coma 
Scale scores of less than 14 at baseline had al-
ready met the criterion for the primary outcome 
before enrollment, such patients were not in-
cluded in the primary analyses but were included 
in the secondary analyses. Distinct encounters 
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with the same patient were considered to be in-
dependent events. Given that patients who under-
went randomization a second time could have 
been randomly assigned to a treatment regimen 
that was different from the first regimen they 
had been assigned to, a single patient could be 
represented in more than one treatment group 
in the analyses. Cochran–Mantel–Haenszel tests 
were used to test the effects of the rate of ad-
ministration and of the sodium chloride con-
tent of the f luid. Each of these factors was 
tested with the use of P values that were ad-
justed for multiplicity at a two-sided alpha level 
of 0.025.
We analyzed the magnitude of the decline in 
the Glasgow Coma Scale score and the duration 
of time in which the Glasgow Coma Scale score 
was less than 14 using Van Elteren tests, with 
adjustment for stratification variables. The inci-
dence of clinically apparent brain injury was 
evaluated with the use of a Cochran–Mantel–
Haenszel test. We tested for treatment interac-
tions using regression models. To evaluate digit-
span scores, we used a linear mixed-effects 
model to estimate time-dependent effects of the 
rate of administration and the sodium chloride 
content of the f luid. We assigned a digit-span 
score of zero in cases in which a patient had a 
Glasgow Coma Scale score of less than 14 to 
account for digit-span scores that could not be 
measured owing to mental status alterations. 
A random intercept and slope term for patient 
encounters and similar fixed terms for trial cen-
ters were included in the model.
The main analysis of memory function was 
based on the average of the children’s correct 
recall rates of items in association with their 
color background or spatial location. Scores were 
excluded from the analysis if chance recognition 
of previously viewed items was observed (sensi-
tivity index of <0.50; 5% of tests). Memory scores 
and IQ were compared with the use of a Van 
Elteren test, with adjustment for stratification 
variables. In cases in which a patient had more 
than one valid follow-up measurement, only the 
first measurement was included in the analysis. 
Significance levels for digit-span score and mem-
ory function were adjusted for multiple compari-
sons with the use of the Holm procedure.
We also analyzed treatment effects in pre-
specified subgroups defined according to age 
(<6 years vs. ≥6 years), Glasgow Coma Scale score 
at baseline, and history of diabetic ketoacidosis 
(yes vs. no) using regression models, with ad-
justment for stratification variables. The overall 
type I error rate for the subgroup analyses was 
preserved at 0.05. Using the same methods, we 
explored treatment effects in eight subgroups 
defined according to various baseline character-
istics that are associated with more severe dia-
betic ketoacidosis; results from four of these sub-
groups are reported and should be interpreted 
with caution owing to multiple comparisons. 
The analyses of statistical power and sample 
size have been described previously.17 Our target 
sample size was 1360 patient encounters involv-
ing children who had baseline Glasgow Coma 
Scale scores of 14 or 15 (i.e., 1360 episodes of 
diabetic ketoacidosis that could be included in the 
primary analysis).
Two-sided O’Brien–Fleming stopping bound-
aries at the time of each interim efficacy analysis 
were calculated with the use of the alpha-spend-
ing function approach. The thresholds for sig-
nificance at the first, second, and third interim 
analyses were 0.000006, 0.0008, and 0.0075, re-
spectively. No safety concerns were identified, 
and the trial proceeded to completion.
R esult s
Patients
From February 2011 through September 2016, a 
total of 1255 children were randomly assigned 
to one of the four treatment regimens (Table 1). 
Among these 1255 patients, 132 had a second 
episode of diabetic ketoacidosis and underwent 
randomization a second time during the trial. 
Two additional patients who had a third episode 
of diabetic ketoacidosis inadvertently underwent 
randomization a third time. Therefore, a total of 
1389 distinct episodes of diabetic ketoacidosis 
were evaluated. Patient enrollment and random-
ization status are shown in Figure 1. Demo-
graphic and clinical characteristics of the chil-
dren, including status with respect to history of 
diabetes, did not differ significantly among the 
four groups (Table 2). Adherence to the assigned 
treatment regimens was excellent (Figs. S1 and 
S2 in the Supplementary Appendix, available at 
NEJM.org). Enrollment varied among the emer-
gency departments; the number of patient en-
counters ranged from 23 to 239 (Table S1 in the 
Supplementary Appendix).
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Mental Status during Treatment for Diabetic 
Ketoacidosis
In 1361 episodes of diabetic ketoacidosis (98.0%), 
children presented with Glasgow Coma Scale 
scores of 14 or 15, and these episodes were 
therefore included in the primary analysis. Dur-
ing the course of the trial, the Glasgow Coma 
Scale score declined to below 14 in 48 (3.5%) of 
these episodes (Table 3). A total of 22 episodes 
(1.6%) resulted in the children receiving hyper-
2848 Were eligible
1389   Underwent randomization
4912 Patients met inclusion criteria
2064 Were ineligible
1377 Were transferred from another facility where they
received an initial fluid bolus of >10 ml/kg
527 Received intravenous fluids at a maintenance rate 
or greater for >2 hr
410 Received treatment for diabetic ketoacidosis >4 hr
before eligibility assessment
289 Were withdrawn by physician
101 Were enrolled more than once previously
90 Had preexisting neurologic disease
67 Had a Glasgow Coma Scale score of ≤11
42 Were scheduled to receive or had already received
hyperosmolar therapy
28 Had concurrent alcohol or drug use, head 
trauma, meningitis, or other condition affecting
mental status
2 Were pregnant
2217 Were approached
631 Were not approached
272 Were unable to undergo randomization
within the eligibility time window
264 Were unable to be enrolled owing to lack
of availability of research staff
95 Were not approached for other reasons
1405 Consented
812 Had guardian who did not give consent
16 Did not undergo randomization
344 Were assigned to fast admini-
stration rate and 0.45% sodium
chloride content
337 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment
349 Were assigned to slow admini-
stration rate and 0.9% sodium
chloride content
341 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment
345 Were assigned to slow admini-
stration rate and 0.45% sodium
chloride content
338 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment
351 Were assigned to fast admini-
stration rate and 0.9% sodium
chloride content
345 Had Glasgow Coma Scale
scores of 14 or 15 at enrollment
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osmolar therapy for possible cerebral edema or 
brain injury. In 12 episodes (0.9%), the children 
had clinically apparent brain injury (confirmed 
by adjudication) — a rate that was similar to pre-
viously documented frequencies.1-3 Most of the 12 
patients presented with severe acidosis and hypo-
capnia (Table S2 in the Supplementary Appendix). 
One of the 12 patients died, and the remaining 
patients recovered without overt neurologic 
deficits.
There were no significant differences among 
the groups in the percentage of episodes in 
which the Glasgow Coma Scale score declined to 
below 14, in the magnitude of decline in the 
Glasgow Coma Scale score, or in the duration of 
time in which the Glasgow Coma Scale score 
was less than 14 (Table 3, and Table S3 in the 
Supplementary Appendix). The Breslow–Day test 
for homogeneity of the odds ratios did not pro-
vide evidence against homogeneity (P = 0.39 for 
administration rate; P = 0.67 for sodium chloride 
content). The incidence of clinically apparent 
brain injury was higher in the slow rehydration 
groups than in the fast rehydration groups; how-
ever, the differences were not significant. Digit-
span scores during the episode of diabetic keto-
acidosis did not differ significantly among the 
four groups, although point estimates for the 
rate of improvement in forward digit-span scores 
favored more rapid rehydration (P = 0.06).
Subgroup Analyses of Mental Status
Analyses of the relative risk of a decline to below 
14 in the Glasgow Coma Scale score in sub-
groups defined according to age and history of 
diabetic ketoacidosis among patients who had 
Glasgow Coma Scale scores of 14 or 15 at base-
line did not show differential treatment effects 
(Fig. S3 in the Supplementary Appendix). In the 
subgroups of patients who had more severe dia-
betic ketoacidosis (a pH or partial pressure of 
carbon dioxide [Pco2] level in the lowest quartile 
or a blood urea nitrogen level or glucose level in 
the highest quartile), the percentage of episodes 
in which the Glasgow Coma Scale score declined 
to below 14 and the percentage of episodes in 
which clinically apparent brain injury was con-
firmed did not differ significantly among the 
groups (Table S4 in the Supplementary Appen-
dix). The effect of rehydration rate on forward 
digit-span scores differed in the subgroup defined 
according to Pco2 level (P = 0.03 for the interac-
tion between treatment and Pco2 level), with faster 
improvement in the rapid rehydration groups 
than in the slow rehydration groups among pa-
tients with a low Pco2 level (P = 0.03). The effect 
of rehydration rate on backward digit-span scores 
differed in the subgroup defined according to 
pH level (P = 0.01 for the interaction between 
treatment and pH level), with faster improve-
ment in the rapid rehydration groups than in the 
slow rehydration groups among patients with a 
low pH (P = 0.01).
Neurocognitive Assessments after Recovery 
from Diabetic Ketoacidosis
In all, 1287 episodes occurred in children older 
than 3 years of age who met the criteria for 
follow-up neurocognitive testing. The children 
involved in 387 of these episodes (30.1%) were 
either lost to follow-up or declined to return for 
neurocognitive testing (see “Power and Sample 
Size” in the Supplementary Appendix for sensi-
tivity analyses regarding missing data). Data were 
analyzed for 855 episodes (66.4%), for which 
follow-up occurred within 6 months after the 
patient’s discharge from the hospital (756 with-
in 4 months and 99 between 5 and 6 months). 
There were no significant differences in neuro-
cognitive outcomes after recovery among the 
trial groups (Table S5 in the Supplementary Ap-
pendix).
Figure 1 (facing page). Enrollment and Randomization.
A total of 586 patients met multiple ineligibility criteria. 
Three patients who had a Glasgow Coma Scale score 
of 11 or lower were enrolled before the implementation 
of this exclusion criterion. Patients were permitted to 
undergo randomization a second time if they had a sec-
ond episode of diabetic ketoacidosis during the trial, with 
each randomization considered to be a distinct encoun-
ter; hence, some children are represented more than 
once in this figure. A total of 1255 patients underwent 
randomization initially. Among these 1255 patients, 
132 had a second episode of diabetic ketoacidosis and 
underwent randomization a second time during the trial. 
Two additional patients who had a third episode of dia-
betic ketoacidosis inadvertently underwent randomiza-
tion a third time. Therefore, a total of 1389 distinct epi-
sodes of diabetic ketoacidosis were evaluated, as shown 
here. Enrollment sites were located in Boston, MA, Chi-
cago, IL, Columbus, OH, Denver, CO, Houston, TX, New 
York, NY, Philadelphia, PA, Providence, RI, Sacramento, 
CA, Salt Lake City, UT, St. Louis, MO, Washington, DC, 
and Wilmington, DE.
The New England Journal of Medicine 
Downloaded from nejm.org at Washington University in St. Louis Becker Library on June 19, 2018. For personal use only. No other uses without permission. 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med 378;24 nejm.org June 14, 20182282
Th e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Results among Patients Treated According to 
the Protocol
Fluid hydration regimens that were administered 
in 115 episodes (8.3%), including 107 (7.9%) 
analyzed for the primary outcome, deviated suf-
ficiently from the assigned treatment regimen 
that the rate of administration or sodium chlo-
ride content of the fluid was more similar to 
other treatment regimens than to the assigned 
regimen. We excluded these episodes and re-
peated the analyses to determine whether these 
protocol deviations influenced the outcomes 
(Tables S6 and S7 in the Supplementary Appen-
dix). The results of these analyses showed no 
significant differences among the groups.
Results among Patients According to 
Treatment Received
We modeled continuous versions of fluid admin-
istration rate and sodium chloride content in 
Variable
Fast Administration  
of 0.45% Sodium 
Chloride Solution 
(N = 344)
Fast Administration  
of 0.9% Sodium 
Chloride Solution 
(N = 351)
Slow Administration  
of 0.45% Sodium 
Chloride Solution 
(N = 345)
Slow Administration  
of 0.9% Sodium 
Chloride Solution 
(N = 349)
Demographic characteristics
Age — yr 11.5±4.06 11.8±4.26 11.6±4.09 11.6±3.89
Age <6 yr — no. (%) 43 (12.5) 42 (12.0) 42 (12.2) 35 (10.0)
Race — no./total no. (%)†
White 235/327 (71.9) 232/328 (70.7) 247/331 (74.6) 243/329 (73.9)
Black 73/327 (22.3) 82/328 (25.0) 68/331 (20.5) 63/329 (19.1)
Other 19/327 (5.8) 14/328 (4.3) 16/331 (4.8) 23/329 (7.0)
Hispanic ethnic group — no./total no. (%)†  48/331 (14.5)  62/335 (18.5)  49/329 (14.9)  69/342 (20.2)
Male sex — no. (%) 165 (48.0) 164 (46.7) 158 (45.8) 163 (46.7)
Diabetes history
Previous diagnosis of diabetes — no. (%) 174 (50.6) 182 (51.9) 185 (53.6) 192 (55.0)
Duration of diabetes — yr 4.8±3.1 5.1±3.2 4.9±3.4 4.8±3.3
History of severe hypoglycemia — no./total no. (%)
None 135/170 (79.4) 139/178 (78.1) 144/183 (78.7) 154/188 (81.9)
1 or 2 episodes 20/170 (11.8) 26/178 (14.6) 29/183 (15.8) 25/188 (13.3)
>2 episodes 15/170 (8.8) 13/178 (7.3) 10/183 (5.5) 9/188 (4.8)
Previous episodes of diabetic ketoacidosis  
among patients with known diabetes  
— no./total no. (%)
None 42/173 (24.3) 34/181 (18.8) 60/182 (33.0) 58/189 (30.7)
1 or 2 74/173 (42.8) 83/181 (45.9) 67/182 (36.8) 77/189 (40.7)
>2 57/173 (32.9) 64/181 (35.4) 55/182 (30.2) 54/189 (28.6)
Glycated hemoglobin level in previous yr — %‡ 10.6±2.0 10.8±1.8 10.7±1.9 10.5±2.0
Mental status at randomization
Glasgow Coma Scale score at randomization — no. (%)§
<14 7 (2.0) 6 (1.7) 7 (2.0) 8 (2.3)
14 23 (6.7) 25 (7.1) 26 (7.5) 25 (7.2)
15 314 (91.3) 320 (91.2) 312 (90.4) 316 (90.5)
Forward digit-span recall¶ 7.13±2.39 7.12±2.28 7.25±2.07 7.46±2.37
Backward digit-span recall¶ 5.54±2.31 5.47±2.25 5.51±2.30 5.76±2.31
Table 2. Demographic and Clinical Characteristics of the Trial Population.*
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regression analyses. To account for influences of 
clinical presentation on decisions of the clini-
cians to deviate from assigned treatment regi-
mens, we included covariates that reflected the 
severity of diabetic ketoacidosis (levels of pH, 
Pco2, glucose, sodium, and blood urea nitrogen), 
age, and whether the diabetes was new-onset or 
preexisting. Again, no significant effects of either 
fluid administration rate or sodium chloride con-
tent on acute neurologic outcomes were found 
(data not shown).
Nonneurologic Adverse Events
Hyperchloremic acidosis was more common 
among patients who received fluid that had a 
0.9% sodium chloride content than among those 
who received fluid that had a 0.45% sodium 
chloride content and more common among pa-
tients who received fluid at a rapid rate than 
among those who received fluid at a slow rate 
(Table S8 in the Supplementary Appendix). The 
0.9% sodium chloride regimens were also asso-
ciated with a higher incidence of hypocalcemia 
and hypophosphatemia than were the 0.45% 
sodium chloride regimens. A rapid rate of fluid 
administration was associated with a higher in-
cidence of hypocalcemia but not a higher inci-
dence of hypophosphatemia. Hypoglycemia and 
hypokalemia occurred at similar rates in the four 
groups. Serious adverse events occurred in less 
than 3% of participants (Table 4, and Table S9 
in the Supplementary Appendix). The time to 
resolution of diabetic ketoacidosis and the dura-
tion of hospitalization were similar among the 
groups (Table S10 in the Supplementary Appendix).
Discussion
In this randomized, controlled trial, with a 2-by-2 
factorial design, that involved children with dia-
betic ketoacidosis, there were no significant dif-
ferences in the rate of decline in mental status 
or in the rate of clinically apparent brain injury 
during treatment for diabetic ketoacidosis or in 
neurocognitive function after recovery from dia-
betic ketoacidosis among patients who received 
rehydration fluid at two different administration 
rates and with two different sodium chloride 
contents. The lowest rates of mental status de-
cline and clinically apparent brain injury were in 
Variable
Fast Administration  
of 0.45% Sodium 
Chloride Solution 
(N = 344)
Fast Administration  
of 0.9% Sodium 
Chloride Solution 
(N = 351)
Slow Administration  
of 0.45% Sodium 
Chloride Solution 
(N = 345)
Slow Administration  
of 0.9% Sodium 
Chloride Solution 
(N = 349)
Laboratory values at presentation
Glucose — mg/dl 519±153 524±150 523±170 522±156
Blood urea nitrogen — mg/dl 17±8 17±7 17±9 17±7
pH 7.17±0.09 7.16±0.10 7.16±0.10 7.16±0.11
Sodium — mmol/liter 134±5 134±5 134±5 134±5
Bicarbonate — mmol/liter 9±3 9±3 9±3 9±3
Pco2 — mm Hg 26±7 26±7 26±8 27±7
*  Plus–minus values are means ±SD. There were no significant differences (P<0.05) between the groups in any of the comparisons according 
to Kruskal–Wallis tests for continuous variables and chi-square tests for categorical variables. Patients were permitted to undergo random-
ization a second time if they had a second episode of diabetic ketoacidosis during the trial, with each randomization considered to be a dis-
tinct encounter; therefore, a patient could be represented in more than one group. A total of 132 patients had a second episode of diabetic 
ketoacidosis and underwent randomization a second time during the trial. Two additional patients who had a third episode of diabetic keto-
acidosis inadvertently underwent randomization a third time. Therefore, a total of 1389 distinct episodes of diabetic ketoacidosis were evalu-
ated Data shown are based on encounters. Percentages may not sum to 100 because of rounding. To convert the values for glucose to milli-
moles per liter, multiply by 0.05551. To convert the values for blood urea nitrogen to millimoles per liter, multiply by 0.357.
†  Race and ethnic group were determined by either patient report or review of medical records.
‡  Data were available for 173, 173, 177, and 184 patients in the four listed groups, respectively.
§  Scores range from 3 to 15, with lower scores indicating worse mental status.
¶  Scores range from 0 to 16, with higher scores indicating better short-term memory. In the digit span test, participants are asked to repeat a 
sequence of numbers presented orally. In the “forward” task, participants are asked to repeat numbers in order, as presented. In the “back-
ward” task, participants are asked to list the numbers in reverse order. The test stops when participants report the incorrect sequence twice 
for a given digit-span length.
Table 2. (Continued.)
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the rapid-rehydration groups, although the dif-
ferences from other groups were not significant. 
Furthermore, analyses of the subgroups of pa-
tients who had more severe diabetic ketoacidosis 
suggested faster improvement in digit-span recall 
in the rapid fluid-administration groups than in 
the slow fluid-administration groups. These find-
ings underscore the lack of a causal association 
between rapid fluid administration and diabetic 
ketoacidosis–related brain injury.
Clinically apparent diabetic ketoacidosis–related 
brain injury occurs infrequently but is an impor-
tant cause of neurologic damage and death 
among children with diabetes.1-3,22-24 Subtle brain 
injury often occurs during treatment for diabetic 
ketoacidosis in children and may contribute to 
cognitive decline.4-9 Excessive fluid administra-
tion, which may result in rapid osmotic chang-
es, has been widely suspected to cause brain in-
jury,11,25,26 but a more recent hypothesis suggests 
that cerebral hypoperfusion and the effects of 
reperfusion, along with neuroinflammation, are 
central to diabetic ketoacidosis–related brain 
injury.2,27-29 The latter hypothesis is consistent 
with reports that document symptomatic and 
even fatal brain injury occurring before the ini-
tiation of treatment for diabetic ketoacidosis.2,30 
Furthermore, although cerebral edema is a fea-
ture of clinically apparent brain injury, edema 
often develops hours or days after a diagnosis of 
Variable
Fast Administration  
of 0.45%  
Sodium Chloride 
Solution
Fast Administration  
of 0.9%  
Sodium Chloride 
Solution
Slow Administration  
of 0.45%  
Sodium Chloride 
Solution
Slow Administration  
of 0.9%  
Sodium Chloride 
Solution
Any adverse event — no. of episodes 114 124 118 129
Serious adverse event — no. (%) 5 (4.4) 4 (3.2) 11 (9.3) 10 (7.8)
Outcome — no. (%)
Recovery, with return to baseline 
status
102 (89.5) 109 (87.9) 108 (91.5) 118 (91.5)
Recovery with sequelae 1 (0.9) 1 (0.8) 1 (0.8) 1 (0.8)
Persistence of symptoms 10 (8.8) 14 (11.3) 9 (7.6) 10 (7.8)
Death 1 (0.9) 0 0 0
Severity — no. (%)
Mild 95 (83.3) 96 (77.4) 89 (75.4) 98 (76.0)
Moderate 12 (10.5) 25 (20.2) 22 (18.6) 30 (23.3)
Severe 7 (6.1) 3 (2.4) 7 (5.9) 1 (0.8)
Expected event — no. (%) 58 (50.9) 56 (45.2) 64 (54.2) 68 (52.7)
Common clinical adverse events  
— no. (%)†
Headache 29 (25.4) 16 (12.9) 23 (19.5) 28 (21.7)
Oropharyngeal pain 9 (7.9) 11 (8.9) 10 (8.5) 9 (7.0)
Pyrexia 8 (7.0) 11 (8.9) 8 (6.8) 10 (7.8)
Abdominal pain 2 (1.8) 11 (8.9) 7 (5.9) 3 (2.3)
Constipation 3 (2.6) 4 (3.2) 2 (1.7) 11 (8.5)
*  These data were analyzed in the safety population (all patients who underwent randomization and received any trial fluid). Because patients 
were permitted to undergo randomization twice, a patient could be represented in more than one group. Data are based on patient encoun-
ters (i.e., episodes of diabetic ketoacidoses) rather than on individual patients. An episode in which multiple adverse events of the same 
type occurred is counted once. An episode in which multiple adverse events of different types occurred is counted once for each type of  
adverse event. In cases in which multiple adverse events occurred in an episode, the most serious adverse event was used to describe  
seriousness, outcome, and severity.
†  Common clinical adverse events were events that were reported in six or more patients in any group, excluding adverse events that were 
counted either as trial outcomes (mental status changes or brain injuries) or as expected nonneurologic adverse events (e.g., hypoglycemia 
or electrolyte abnormalities) (Table S8 in the Supplementary Appendix).
Table 4. Adverse Events.*
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brain injury,19 a finding that suggests that edema 
may be a consequence, rather than the cause, of 
brain injury.
Studies involving children with diabetic keto-
acidosis and studies in rodent models suggest 
similarities between diabetic ketoacidosis–related 
brain injury and ischemia–reperfusion injury. 
These include low cerebral blood flow and brain-
cell swelling, along with low levels of high-energy 
phosphates in the brain and elevated lactate 
levels, during untreated episodes of diabetic keto-
acidosis and cerebral hyperemia and vasogenic 
edema during treatment for diabetic ketoacido-
sis.27-29,31-33 Although alterations in cerebral blood 
flow may be involved in diabetic ketoacidosis–
related brain injury, the severity of cerebral hypo-
perfusion is unlikely to be sufficient to cause 
brain injury in the absence of other contributing 
factors. Diabetic ketoacidosis is associated with 
marked systemic increases in inflammatory cyto-
kines and chemokines that may contribute to 
brain injury by activating cerebrovascular endo-
thelia and increasing leukocyte adhesion.16,34-36 
Elevated levels of matrix metalloproteinase may 
promote blood–brain barrier dysfunction.37
The current trial has several limitations. First, 
the fluid administration rates were selected to 
represent upper and lower boundaries of current 
protocols used to treat pediatric diabetic keto-
acidosis. It is possible that the use of administra-
tion rates outside this range may have resulted in 
different outcomes. However, given that the 
lowest rate of decline in mental status occurred 
in the group that received rapid rehydration with 
0.45% sodium chloride solution, it seems un-
likely that larger differences between protocols 
would have instead favored slower rehydration. 
Second, clinically apparent brain injury occurs 
in less than 1% of episodes, making it impracti-
cal to design a trial with sufficient statistical 
power to detect differences in this outcome. We 
used alterations in mental status as an indicator 
of subtle brain injury because children who have 
abnormal Glasgow Coma Scale scores during 
treatment for diabetic ketoacidosis are more 
likely to have subtle cerebral edema (on mag-
netic resonance imaging) than those who have 
normal mental status during treatment.31,38 
Nonetheless, it is possible that declines in 
Glasgow Coma Scale scores that occur during 
treatment for diabetic ketoacidosis reflect physi-
ological processes that are different from those 
responsible for clinically apparent brain injury. 
Third, statistical power may have been reduced 
by the inclusion of repeat episodes, although such 
a reduction would be small.
In conclusion, in this prospective, randomized 
trial, neither the rate of administration nor the 
sodium chloride content of intravenous fluids 
significantly influenced neurologic outcomes of 
diabetic ketoacidosis in children.
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